Scribe Therapeutics Inc. Common Stock (SCTX) - Net Assets
Based on the latest financial reports, Scribe Therapeutics Inc. Common Stock (SCTX) has net assets worth $-158.74 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($65.21 Million) and total liabilities ($223.95 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. For live market cap and overall valuation, see Scribe Therapeutics Inc. Common Stock market cap and net worth.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-158.74 Million |
| % of Total Assets | -243.43% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Scribe Therapeutics Inc. Common Stock - Net Assets Trend (2024–2025)
This chart illustrates how Scribe Therapeutics Inc. Common Stock's net assets have evolved over time, based on quarterly financial data.
Annual Net Assets for Scribe Therapeutics Inc. Common Stock (2024–2025)
The table below shows the annual net assets of Scribe Therapeutics Inc. Common Stock from 2024 to 2025. See SCTX equity financing ratio to measure how much of total assets are equity-financed.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-143.42 Million | -13.95% |
| 2024-12-31 | $-125.86 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Scribe Therapeutics Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2180800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $14.29 Million | % |
| Total Equity | $-143.42 Million | 100.00% |
Scribe Therapeutics Inc. Common Stock Competitors by Market Cap
The table below lists competitors of Scribe Therapeutics Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
LPKF Laser & Electronics AG
F:LPK
|
$379.47 Million |
|
Shandong Hiking International Co Ltd Class A
SHG:600735
|
$379.60 Million |
|
Dipula Income Fund Ltd
JSE:DIB
|
$379.66 Million |
|
Grand Korea Leisure Co. Ltd
KO:114090
|
$379.78 Million |
|
Shui On Land Limited
F:OL5
|
$379.24 Million |
|
Beijing HuaYuanYiTong Thermal Technology Co Ltd
SHE:002893
|
$379.23 Million |
|
Tubacex S.A
MC:TUB
|
$379.10 Million |
|
Wenfeng Great World Chain Development Corp
SHG:601010
|
$378.48 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Scribe Therapeutics Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -125,859,000 to -143,419,000, a change of -17,560,000.
- Net loss of 21,808,000 reduced equity.
- Other factors increased equity by 4,248,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-21.81 Million | -15.21% |
| Other Changes | $4.25 Million | +2.96% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Scribe Therapeutics Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently Scribe Therapeutics Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -42.62%
- • Asset Turnover: 0.65x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (0.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2024 | 0.00% | -174.32% | 0.21x | 0.00x | $-35.20 Million |
| 2025 | 0.00% | -42.62% | 0.65x | 0.00x | $-7.47 Million |
Industry Comparison
This section compares Scribe Therapeutics Inc. Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $49,343,171
- Average return on equity (ROE) among peers: -63.98%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Scribe Therapeutics Inc. Common Stock (SCTX) | $-158.74 Million | 0.00% | N/A | $379.31 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $148.49 Million |
| Abcellera Biologics Inc (ABCL) | $11.61 Million | 2.66% | 0.85x | $2.99 Billion |
| Abeona Therapeutics Inc (ABEO) | $-5.83 Million | 0.00% | 0.00x | $335.61 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $1.59 Billion |
| Arbutus Biopharma Corp (ABUS) | $59.19 Million | -23.76% | 0.21x | $906.70 Million |
| ABVC Biopharma Inc (ABVC) | $-2.99 Million | 0.00% | 0.00x | $23.14 Million |
| Abivax SA American Depositary Shares (ABVX) | $25.93 Million | -163.70% | 3.21x | $10.02 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $12.11 Million | -372.67% | 3.10x | $5.07 Billion |
About Scribe Therapeutics Inc. Common Stock
Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States. The company offers STX-1150 designed to be a single-course in vivo epigenetic silencing treatment targeting the PCSK9 gene; STX-1200… Read more